Effective treatments for COVID-19 will continue to be vital to manage the virus even as vaccines are rolled out in the UK and globally, including for those who cannot be vaccinated, for example because they are immunocompromised. Finding effective treatments will reduce risk to lives and serious illness for people who do contract the virus and support the return to normal life.
The Government is delivering a world-leading programme of clinical trials, including RECOVERY (the world’s largest randomised controlled clinical trial for treatments in the hospitalised setting) and REMAP-CAP, which are testing potential treatments in primary, acute and intensive care respectively. Early indications from the global REMAP-CAP trial this month suggest that tocilizumab may play an important role in improving the outcome of patients in ICU.
More results are expected for immunomodulatory drugs, anti-virals, antibiotics, therapeutic antibodies and convalescent plasma for patients in different stages of the illness and various care settings, including hospitals and intensive care, primary care and care home patients.
Antibodies are an important component in managing COVID-19 in everyday lives. They can be used therapeutically for infected patients and prophylactically for immunocompromised patients who cannot receive vaccines. The Government is COVID-19 WINTER PLAN 15 supporting efforts to research and produce effective antibody therapies and phase III trials are ongoing. 35. The Government will continue to recruit into clinical trials to further global understanding of which therapeutics are effective, and make proven interventions available to the NHS. 36. Patients who have received a positive COVID-19 test may be eligible to participate in a clinical trial: see https://bepartofresearch.nihr.ac.uk for details.
The Government also urges those who have recovered from COVID-19 to consider donating convalescent plasma to help others. Further details can be found HERE.